The cluster shows passive accumulation during a sharp price decline, which may indicate bottom-fishing or index rebalancing rather than strong fundamental conviction. Traders should monitor for stabilization in share price and any upcoming clinical catalysts for KROS, as the lack of active manager participation limits the bullish signal strength.
KROS drugs
KROS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $13.91entry
- T+1 · 9mo ago −3.67%α −2.75% · $13.40
- T+5 · 8mo ago −18.40%α −17.20% · $11.35
- T+20 · 8mo ago −23.22%α −15.28% · $10.68
- T+60 · 6mo ago −19.27%α −28.59% · $11.23
How similar events traded
Executive Summary
Three major passive institutions, Morgan Stanley, Wells Fargo, and UBS, increased their positions in Keros Therapeutics (KROS) during Q4 2024, with UBS doubling its stake and Morgan Stanley adding nearly 300K shares. Despite the share count increases, the total value of these positions declined significantly due to falling stock price, resulting in a net decrease in market value of $11.7M across the group.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$11.7M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | ADD | +79.8% | $10.4M | -$10.8M |
| Wells Fargo | ADD | +37.6% | $241.0K | -$401.2K |
| UBS | DOUBLED | +212.9% | $2.8M | -$477.2K |
Key Facts
- Morgan Stanley increased shares by 79.8% (365.3K → 656.8K), but position value dropped from $21.2M to $10.4M
- Wells Fargo added 4.2K shares (+37.6%), yet value fell from $642K to $241K
- UBS more than doubled its stake (+212.9%, 55.9K → 174.9K), but value decreased from $3.2M to $2.8M
- All three institutions are classified as mega-passive, suggesting index-driven or model-based allocation rather than active conviction
- Aggregate buyer count: 3, seller count: 0; total net value change: -$11.7M
Financial Impact
3 institutions added $13.4M in new share value (based on current prices) while experiencing a combined paper loss of $11.7M on existing holdings due to price decline
Risk Factors
- All buying activity came from passive managers, reducing the signal strength of institutional conviction
- Significant drop in position values despite share increases suggests substantial stock price depreciation during the quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-KROS-2024-Q4 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers